Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Malaria Vaccine Candidates R78C and RH5.1/R21 in Children in Burkina Faso
NCT07183371Phase 2Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Dec 2025
- Primary completion
- Mar 2027
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of R78C, RH5.1, R21/Matrix-M in malaria, sponsored by University of Oxford. Started Dec 2025; status: active, not recruiting.
02
Drugs
R78CRH5.1R21/Matrix-M
03
Conditions
malaria
Beyond the preview
Go deeper on NCT07183371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07183371.